CD274 and renal cell carcinoma: Similarly, CAR T-cells that secrete antibodies that block PD-L1, the ligand for PD-1, have demonstrated enhanced efficacy in models of pancreatic cancer (102) and renal cell carcinoma (RCC) (103).